Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 4, 2013, Pages 430-437

  Gustavsson, A ^a,b,c   Magnuson, A ^a   Blomberg, B ^a   Andersson, M ^a   Halfvarson, J ^a,b   Tysk, C ^a,b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY   (Sweden)

^c Karlstad Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; BALLOON; BALLOON DILATATION; COLONOSCOPE; CROHN DISEASE; ENDOSCOPIC BALLOON DILATION; ENDOSCOPIC THERAPY; FEMALE; FOLLOW UP; HUMAN; INTESTINE RESECTION; INTESTINE STENOSIS; INTESTINE SURGERY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REPEAT PROCEDURE; RETROSPECTIVE STUDY; SMOKING; STRICTUREPLASTY;

ADULT; AZATHIOPRINE; CROHN DISEASE; ENDOSCOPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL OBSTRUCTION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 84872687028     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12176     Document Type: Article

References (38)

1. De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV,. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis 2012; 18: 758-77.
2. Yamamoto T,. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005; 11: 3971-9.
3. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L,. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther 2012; 35: 625-33.
4. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M,. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-63.
5. McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M,. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum 2009; 52: 919-27.
6. Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA,. Reoperative rates for Crohn's disease following strictureplasty. Long-term analysis. Dis Colon Rectum 1996; 39: 1199-203.
7. Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD,. Strictureplasty for Crohn's disease: meta-analysis. Dis Colon Rectum 2000; 43: 911-9.
8. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP,. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23: 1213-21.
9. Wibmer AG, Kroesen AJ, Grone J, Buhr HJ, Ritz JP,. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease-review of the literature. Int J Colorectal Dis 2010; 25: 1149-57.
10. Gustavsson A, Magnuson A, Blomberg B, Andersson M, Halfvarson J, Tysk C,. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. Aliment Pharmacol Ther 2012; 36: 151-8.
11. Thienpont C, D'Hoore A, Vermeire S, et al,. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut 2010; 59: 320-4.
12. Couckuyt H, Gevers AM, Coremans G, Hiele M, Rutgeerts P,. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut 1995; 36: 577-80.
13. Scimeca D, Mocciaro F, Cottone M, et al,. Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. Dig Liver Dis 2011; 43: 121-5.
14. Hassan C, Zullo A, De Francesco V, et al,. Systematic review: endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther 2007; 26: 1457-64.
15. Mueller T, Rieder B, Bechtner G, Pfeiffer A,. The response of Crohn's strictures to endoscopic balloon dilation. Aliment Pharmacol Ther 2010; 31: 634-9.
16. Hoffmann JC, Heller F, Faiss S, et al,. Through the endoscope balloon dilation of ileocolonic strictures: prognostic factors, complications, and effectiveness. Int J Colorectal Dis 2008; 23: 689-96.
17. Lakatos PL, Szamosi T, Lakatos L,. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007; 13: 6134-9.
18. Sabate JM, Villarejo J, Bouhnik Y, et al,. Hydrostatic balloon dilatation of Crohn's strictures. Aliment Pharmacol Ther 2003; 18: 409-13.
19. Morini S, Hassan C, Lorenzetti R, et al,. Long-term outcome of endoscopic pneumatic dilatation in Crohn's disease. Dig Liver Dis 2003; 35: 893-7.
20. Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP,. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol 2003; 15: 485-8.
21. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6.
22. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A): 5-36.
23. Panes J, Bouzas R, Chaparro M, et al,. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011; 34: 125-45.
24. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S,. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462-71.
25. Lindberg E, Jarnerot G, Huitfeldt B,. Smoking in Crohn's disease: effect on localisation and clinical course. Gut 1992; 33: 779-82.
26. Danese S, Fiorino G, Reinisch W,. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011; 34: 1-10.
27. Lindberg E, Tysk C, Andersson K, Jarnerot G,. Smoking and inflammatory bowel disease. A Case Control Study. Gut 1988; 29: 352-7.
28. Verschuere S, De Smet R, Allais L, Cuvelier CA,. The effect of smoking on intestinal inflammation: what can be learned from animal models? J Crohns Colitis 2012; 6: 1-12.
29. Raedler A, Peters J, Schreiber S,. Treatment with azathioprine and budesonide prevents recurrence of ileocolonic stenosis after endoscopic dilation in Crohn's disease. Gastroenterology 1997; 112 (Suppl. 1): A1067.
30. Prud'homme GJ,. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077-91.
31. Oshitani N, Yamagami H, Watanabe K, Higuchi K, Arakawa T,. Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease. Gut 2007; 56: 599-600.
32. Holtmann M, Wanitschke R, Helisch A, Bartenstein P, Galle PR, Neurath M,. Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease. Z Gastroenterol 2003; 41: 11-7.
33. Louis E, Boverie J, Dewit O, Baert F, De Vos M, D'Haens G,. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007; 70: 15-9.
34. Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soule JC,. Infliximab treatment for symptomatic Crohn's disease strictures. Aliment Pharmacol Ther 2009; 29: 279-85.
35. Sorrentino D, Terrosu G, Vadala S, Avellini C,. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease. Digestion 2007; 75: 22-4.
36. Swaminath A, Lichtiger S,. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis 2008; 14: 213-6.
37. Ferlitsch A, Reinisch W, Puspok A, et al,. Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures. Endoscopy 2006; 38: 483-7.
38. Johnson GJ, Cosnes J, Mansfield JC,. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 921-31.